Simon Lea
Overview
Explore the profile of Simon Lea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
496
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lea S, Higham A, Beech A, Singh D
Eur Respir Rev
. 2023 Oct;
32(170).
PMID: 37852657
Inhaled corticosteroids (ICS) are the most commonly used anti-inflammatory drugs for the treatment of COPD. COPD has been previously described as a "corticosteroid-resistant" condition, but current clinical trial evidence shows...
2.
Currie C, Framroze B, Singh D, Lea S, Bjerknes C, Hermansen E
Biomedicines
. 2022 Oct;
10(10).
PMID: 36289834
Eosinophils are a major driver of inflammation in a number of human diseases, including asthma. Biologic therapies targeting IL-5 have enabled better control of severe eosinophilic asthma, but no such...
3.
Lea S, Beech A, Baker J, Gaskell R, Pindolia D, Dikwa A, et al.
ERJ Open Res
. 2022 Aug;
8(3).
PMID: 35923420
COPD patients have increased susceptibility to airway bacterial colonisation. and are three of the most common respiratory bacterial species in COPD. colonisation but not other bacteria, in COPD patients is...
4.
Baker J, Baba-Dikwa A, Shah R, Lea S, Singh D
Life Sci
. 2022 Jul;
305:120794.
PMID: 35835251
Aims: Colonisation with non-typeable Haemophilus influenzae (NTHi) is common in COPD. Iron is required by bacteria for nutrition. Gallium is imported into bacteria using iron import proteins. Gallium cannot fulfill...
5.
Li J, Baker J, Higham A, Shah R, Montero-Fernandez A, Murray C, et al.
Inflammopharmacology
. 2022 Apr;
30(4):1431-1443.
PMID: 35441963
Background: Nrf2 regulates cellular antioxidant defence in lung cells, including epithelial cells and alveolar macrophages (AM). The Nrf2/Keap-1 pathway can be modulated by activators with different modes of action; electrophilic...
6.
Higham A, Beech A, Jackson N, Lea S, Singh D
Eur Respir J
. 2022 Feb;
59(5).
PMID: 35210322
No abstract available.
7.
Higham A, Baker J, Jackson N, Shah R, Lea S, Singh D
Cells
. 2022 Jan;
11(1).
PMID: 35011566
Pulmonary iron levels are increased in chronic obstructive pulmonary disease (COPD) patients. Iron causes oxidative stress and is a nutrient for pathogenic bacteria. Iron may therefore play an important role...
8.
Baker J, Hammond M, Dungwa J, Shah R, Montero-Fernandez A, Higham A, et al.
Biomedicines
. 2021 Dec;
9(12).
PMID: 34944755
Lung macrophage iron levels are increased in COPD patients. Lung macrophage iron levels are thought to be increased by cigarette smoke, but the role of red blood cells (RBCs) as...
9.
Singh D, Lea S, Mathioudakis A
Drugs
. 2021 Nov;
81(16):1821-1830.
PMID: 34731461
Phosphodiesterase (PDE) 4 inhibitors prevent the metabolism of cyclic adenosine monophosphate, thereby reducing inflammation. Inhaled PDE4 inhibitors aim to restrict systemic drug exposure to enhance the potential for clinical benefits...
10.
Beech A, Lea S, Li J, Jackson N, Mulvanny A, Singh D
Biomedicines
. 2021 Oct;
9(10).
PMID: 34680454
Background: Chronic obstructive pulmonary disease (COPD) inflammatory endotypes are associated with different airway microbiomes. We used quantitative polymerase chain reaction (qPCR) analysis of sputum samples to establish the bacterial load...